Literature DB >> 23047291

A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT.

Chad C Brown1, Tammy M Havener, Marisa W Medina, J Todd Auman, Lara M Mangravite, Ronald M Krauss, Howard L McLeod, Alison A Motsinger-Reif.   

Abstract

OBJECTIVE: Recently, lymphoblastoid cell lines (LCLs) have emerged as an innovative model system for mapping gene variants that predict the dose response to chemotherapy drugs.
METHODS: In the current study, this strategy was expanded to the in-vitro genome-wide association approach, using 516 LCLs derived from a White cohort to assess the cytotoxic response to temozolomide.
RESULTS: Genome-wide association analysis using ∼2.1 million quality-controlled single-nucleotide polymorphisms (SNPs) identified a statistically significant association (P<10(-8)) with SNPs in the O(6)-methylguanine-DNA methyltransferase (MGMT) gene. We also show that the primary SNP in this region is significantly associated with the differential gene expression of MGMT (P<10(-26)) in LCLs and differential methylation in glioblastoma samples from The Cancer Genome Atlas.
CONCLUSION: The previously documented clinical and functional relationships between MGMT and temozolomide response highlight the potential of well-powered genome-wide association studies of the LCL model system to identify meaningful genetic associations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23047291      PMCID: PMC3691078          DOI: 10.1097/FPC.0b013e3283589c50

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  25 in total

1.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

2.  MENDELIAN PROPORTIONS IN A MIXED POPULATION.

Authors:  G H Hardy
Journal:  Science       Date:  1908-07-10       Impact factor: 47.728

3.  Quantitative trait locus analysis reveals two intragenic sites that influence O6-alkylguanine-DNA alkyltransferase activity in peripheral blood mononuclear cells.

Authors:  Geoffrey P Margison; Jim Heighway; Steven Pearson; Gail McGown; Mary R Thorncroft; Amanda J Watson; Kathryn L Harrison; Sarah J Lewis; Klaus Rohde; Philip V Barber; Paul O'Donnell; Andrew C Povey; Mauro F Santibáñez-Koref
Journal:  Carcinogenesis       Date:  2005-04-14       Impact factor: 4.944

4.  Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS.

Authors:  Dan L Nicolae; Eric Gamazon; Wei Zhang; Shiwei Duan; M Eileen Dolan; Nancy J Cox
Journal:  PLoS Genet       Date:  2010-04-01       Impact factor: 5.917

Review 5.  Genotype imputation.

Authors:  Yun Li; Cristen Willer; Serena Sanna; Gonçalo Abecasis
Journal:  Annu Rev Genomics Hum Genet       Date:  2009       Impact factor: 8.929

6.  Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study.

Authors:  Joel A Simon; Feng Lin; Stephen B Hulley; Patricia J Blanche; David Waters; Stephen Shiboski; Jerome I Rotter; Deborah A Nickerson; Huiying Yang; Mohammed Saad; Ronald M Krauss
Journal:  Am J Cardiol       Date:  2006-01-27       Impact factor: 2.778

Review 7.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Authors:  Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

8.  Accounting for multiple comparisons in a genome-wide association study (GWAS).

Authors:  Randall C Johnson; George W Nelson; Jennifer L Troyer; James A Lautenberger; Bailey D Kessing; Cheryl A Winkler; Stephen J O'Brien
Journal:  BMC Genomics       Date:  2010-12-22       Impact factor: 3.969

9.  A comparison of association methods for cytotoxicity mapping in pharmacogenomics.

Authors:  Chad Brown; Tammy M Havener; Lorraine Everitt; Howard McLeod; Alison A Motsinger-Reif
Journal:  Front Genet       Date:  2011-12-14       Impact factor: 4.599

10.  SNPinProbe_1.0: a database for filtering out probes in the Affymetrix GeneChip human exon 1.0 ST array potentially affected by SNPs.

Authors:  Shiwei Duan; Wei Zhang; Wasim Kamel Bleibel; Nancy Jean Cox; M Eileen Dolan
Journal:  Bioinformation       Date:  2008-08-01
View more
  26 in total

1.  Evaluating the role of admixture in cancer therapy via in vitro drug response and multivariate genome-wide associations.

Authors:  John Jack; Tammy M Havener; Howard L McLeod; Alison A Motsinger-Reif; Matthew Foster
Journal:  Pharmacogenomics       Date:  2015-08-28       Impact factor: 2.533

Review 2.  Implications of genome-wide association studies in cancer therapeutics.

Authors:  Jai N Patel; Howard L McLeod; Federico Innocenti
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

3.  Diversity in non-repetitive human sequences not found in the reference genome.

Authors:  Birte Kehr; Anna Helgadottir; Pall Melsted; Hakon Jonsson; Hannes Helgason; Adalbjörg Jonasdottir; Aslaug Jonasdottir; Asgeir Sigurdsson; Arnaldur Gylfason; Gisli H Halldorsson; Snaedis Kristmundsdottir; Gudmundur Thorgeirsson; Isleifur Olafsson; Hilma Holm; Unnur Thorsteinsdottir; Patrick Sulem; Agnar Helgason; Daniel F Gudbjartsson; Bjarni V Halldorsson; Kari Stefansson
Journal:  Nat Genet       Date:  2017-02-27       Impact factor: 38.330

4.  The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.

Authors:  Erika L Moen; Amy L Stark; Wei Zhang; M Eileen Dolan; Lucy A Godley
Journal:  Mol Cancer Ther       Date:  2014-02-25       Impact factor: 6.261

5.  Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines.

Authors:  Chad C Brown; Tammy M Havener; Marisa W Medina; John R Jack; Ronald M Krauss; Howard L McLeod; Alison A Motsinger-Reif
Journal:  Pharmacogenomics       Date:  2014-02       Impact factor: 2.533

Review 6.  Cancer pharmacogenomics: early promise, but concerted effort needed.

Authors:  Howard L McLeod
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

7.  Lymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model.

Authors:  J Jack; D Rotroff; A Motsinger-Reif
Journal:  Curr Mol Med       Date:  2014       Impact factor: 2.222

8.  SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing MGMT-Methylated Colorectal Cancer.

Authors:  Joice Kuroiwa-Trzmielina; Fan Wang; Robert W Rapkins; Robyn L Ward; Daniel D Buchanan; Aung Ko Win; Mark Clendenning; Christophe Rosty; Melissa C Southey; Ingrid M Winship; John L Hopper; Mark A Jenkins; Jake Olivier; Nicholas J Hawkins; Megan P Hitchins
Journal:  Clin Cancer Res       Date:  2016-06-07       Impact factor: 12.531

9.  Lymphoblastoid cell lines in pharmacogenomics: how applicable are they to clinical outcomes?

Authors:  Amy L Stark; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2013-04       Impact factor: 2.533

10.  Genetic and epigenetic variants contributing to clofarabine cytotoxicity.

Authors:  Michael T Eadon; Heather E Wheeler; Amy L Stark; Xu Zhang; Erika L Moen; Shannon M Delaney; Hae Kyung Im; Patrick N Cunningham; Wei Zhang; M Eileen Dolan
Journal:  Hum Mol Genet       Date:  2013-05-29       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.